Protein Kinase Inhibitors: all 15,147 studies that test it

Page 30 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingNCT04607421Phase 3Results posted
• A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingNCT04606771Phase 2Results posted
• Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric AdenocarcinomaTerminatedNCT04604132Phase 1/2Results posted
• Zanubrutinib in Patients With IgG4-Related DiseaseCompletedNCT04602598Phase 2Results posted
• Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial CarcinomaTerminatedNCT04601857Phase 2Results posted
• Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisCompletedNCT04598269Phase 2Results posted
• Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC InfantsCompletedNCT04595513Phase 1/2Results posted
• A Study of Adavosertib as Treatment for Uterine Serous CarcinomaCompletedNCT04590248Phase 2Results posted
• Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal MelanomaTerminatedNCT04589832Phase 1/2Results posted
• Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumActive, not recruitingNCT04589650Phase 2Results posted
• Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)TerminatedNCT04585815Phase 1/2Results posted
• To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple MyelomaTerminatedNCT04582539Phase 1/2Results posted
• Tofacitinib For Treatment Of Chronic PouchitisTerminatedNCT04580277Phase 2Results posted
• Open-Label Surufatinib in European Patients With NETTerminatedNCT04579679Phase 2Results posted
• Fostamatinib for Hospitalized Adults With COVID-19CompletedNCT04579393Phase 2Results posted
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
• A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT04577963Phase 1/2Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 1Results posted
• Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).TerminatedNCT04566133Phase 2Results posted
• A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerCompletedNCT04564027Phase 2Results posted
• Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)CompletedNCT04562766Phase 3Results posted
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingNCT04557956Phase 1/2Results posted
• Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerCompletedNCT04555837Phase 1/2Results posted
• Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerCompletedNCT04552769Phase 2Results posted
• Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell MalignanciesCompletedNCT04551963Phase 1Results posted
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)TerminatedNCT04551066Phase 3Results posted
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)TerminatedNCT04551053Phase 3Results posted
• A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS LymphomasActive, not recruitingNCT04548648Phase 2Results posted
• Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PKCompletedNCT04546789Phase 1Results posted
• Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaTerminatedNCT04543279Phase 2Results posted
• Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in IndiaCompletedNCT04541706Phase 4Results posted
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerCompletedNCT04539938Phase 2Results posted
• Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)CompletedNCT04535947Phase 2Results posted
• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and IntestinesActive, not recruitingNCT04535401Phase 1Results posted
• A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.TerminatedNCT04534283Phase 2Results posted
• Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With VitiligoCompletedNCT04530344Phase 3Results posted
• Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With PexidartinibCompletedNCT04526704Phase 4Results posted
• Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)TerminatedNCT04524858Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)CompletedNCT04518995Phase 3Results posted
• PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATATerminatedNCT04517864Phase 2Results posted
• ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell LymphomaTerminatedNCT04517435Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGSTerminatedNCT04517253Phase 2/3Results posted
• Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)TerminatedNCT04515394Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Losmapimod Safety and Efficacy in COVID-19TerminatedNCT04511819Phase 3Results posted
• Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsCompletedNCT04511533Phase 4Results posted
• Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone LymphomaCompletedNCT04508647Phase 2Results posted
• Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast CancerTerminatedNCT04504331Phase 1Results posted
• A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaTerminatedNCT04501614Phase 1/2Results posted
• Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerCompletedNCT04499924Phase 2/3Results posted
• Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19TerminatedNCT04497948Phase 1Results posted
• Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line TherapyTerminatedNCT04497038Phase 1/2Results posted
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's SyndromeActive, not recruitingNCT04496960Phase 1/2Results posted
• MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)CompletedNCT04495621Phase 1/2Results posted
• Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyActive, not recruitingNCT04493853Phase 3Results posted
• Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaCompletedNCT04493203Phase 2Results posted
• Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis LipoidicaCompletedNCT04492618Phase 2Results posted
• A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTActive, not recruitingNCT04488822Phase 3Results posted
• Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF AlterationsTerminatedNCT04488003Phase 2Results posted
• Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)CompletedNCT04487886Phase 2Results posted
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Phase 3Results posted
• A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)CompletedNCT04481685Phase 2Results posted
• Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT04477486Phase 2Results posted
• To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT04476043Phase 2Results posted
• A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic ImpairmentCompletedNCT04473664Phase 1Results posted
• Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy AdultsCompletedNCT04472650Phase 1Results posted
• Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyCompletedNCT04471428Phase 3Results posted
• The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy MalesCompletedNCT04470908Phase 1Results posted
• Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaCompletedNCT04467840Phase 2/3Results posted
• Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid CancersCompletedNCT04462471Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersActive, not recruitingNCT04460937Phase 1Results posted
• A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy ParticipantsCompletedNCT04459598Phase 1Results posted
• A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy ParticipantsCompletedNCT04459585Early Phase 1Results posted
• GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT04456998Phase 2Results posted
• INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersCompletedNCT04455841Phase 1/2Results posted
• A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCCompletedNCT04452877Phase 2Results posted
• A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease StateCompletedNCT04451772Phase 2Results posted
• A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)CompletedNCT04447755Phase 2Results posted
• Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHDTerminatedNCT04446182Phase 2Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingNCT04446117Phase 3Results posted
• A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult ParticipantsCompletedNCT04441255Phase 1Results posted
• Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19CompletedNCT04440007Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)Active, not recruitingNCT04439357Phase 2Results posted
• Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)Active, not recruitingNCT04439344Phase 2Results posted
• Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)Active, not recruitingNCT04439331Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)Active, not recruitingNCT04439318Phase 2Results posted
• Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingNCT04439292Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)Active, not recruitingNCT04439279Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)Active, not recruitingNCT04439266Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)Active, not recruitingNCT04439253Phase 2Results posted
• Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)CompletedNCT04439240Phase 2Results posted
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)Active, not recruitingNCT04439227Phase 2Results posted
• Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)Active, not recruitingNCT04439201Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)Active, not recruitingNCT04439188Phase 2Results posted
• Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)Active, not recruitingNCT04439175Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)Active, not recruitingNCT04439149Phase 2Results posted
• Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingNCT04439136Phase 2Results posted
• Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)Active, not recruitingNCT04439123Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)TerminatedNCT04439071Phase 2/3Results posted

← Protein Kinase Inhibitors overview